Safety in Subsequent Lines of Therapy in Patients With Relapsed/Refractory Follicular Lymphoma

Overview

Journal J Adv Pract Oncol

Date 2025 Jan 13

PMID 39802526

Authors

Tajuana Bradley

Mark Davis

Julie Martin

Susan Woodward

Affiliations

Soon will be listed here.

Abstract

Follicular lymphoma (FL) is a disease often characterized by chronic and successive relapses after first-line chemoimmunotherapy. Although chemoimmunotherapy and combination therapy, such as lenalidomide with rituximab, are well established in the treatment sequence of FL, there is a need to streamline treatment options and determine placement of novel agents, such as chimeric antigen receptor T-cell therapy, an enhancer of zeste homolog 2 inhibitor, or a phosphoinositide 3 kinase inhibitor, into the treatment landscape. As such, the purpose of this review is to compare the safety profiles of approved agents in subsequent lines of therapy for relapsed or refractory FL and to assess how the management of adverse events may impact treatment choice.

References

Yanez L, Sanchez-Escamilla M, Perales M . CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere. 2019; 3(2):e186. PMC: 6746032. DOI: 10.1097/HS9.0000000000000186. View

Casulo C, Byrtek M, Dawson K, Zhou X, Farber C, Flowers C . Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-22. PMC: 4879714. DOI: 10.1200/JCO.2014.59.7534. View

Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino S . Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 32(3):298-308. DOI: 10.1016/j.annonc.2020.11.008. View

Bodor C, Grossmann V, Popov N, Okosun J, ORiain C, Tan K . EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013; 122(18):3165-8. PMC: 3814734. DOI: 10.1182/blood-2013-04-496893. View

Friedberg J, Taylor M, Cerhan J, Flowers C, Dillon H, Farber C . Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009; 27(8):1202-8. PMC: 2738614. DOI: 10.1200/JCO.2008.18.1495. View

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C . Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017; 377(14):1331-1344. DOI: 10.1056/NEJMoa1614598. View

Chauhan A, Cheson B . Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic. Cancer Manag Res. 2021; 13:677-692. PMC: 7846853. DOI: 10.2147/CMAR.S201024. View

Skarbnik A, Patel K . Treatment selection for patients with relapsed or refractory follicular lymphoma. Front Oncol. 2023; 13:1120358. PMC: 10028236. DOI: 10.3389/fonc.2023.1120358. View

Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhu J . AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019; 37(14):1188-1199. PMC: 7035866. DOI: 10.1200/JCO.19.00010. View

10.

Gea-Banacloche J . Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. Semin Hematol. 2023; 60(1):52-58. PMC: 10119490. DOI: 10.1053/j.seminhematol.2023.02.003. View

11.

Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Diaz de Heredia C, Fortuny-Guasch C . Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2020; 49(2):215-231. PMC: 7518951. DOI: 10.1007/s15010-020-01521-5. View

12.

Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S . Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020; 21(11):1433-1442. PMC: 8427481. DOI: 10.1016/S1470-2045(20)30441-1. View

13.

Javarappa K, Tsallos D, Heckman C . A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. SLAS Discov. 2018; 23(7):687-696. DOI: 10.1177/2472555218777968. View

14.

Sun L, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y . Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7(287):287ra70. DOI: 10.1126/scitranslmed.aaa4802. View

15.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting K, Rosen M . EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013; 23(5):677-92. PMC: 3681809. DOI: 10.1016/j.ccr.2013.04.011. View

16.

Baker T, Nerle S, Pritchard J, Zhao B, Rivera V, Garner A . Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget. 2015; 6(32):32646-55. PMC: 4741719. DOI: 10.18632/oncotarget.5066. View

17.

Bannerji R, Arnason J, Advani R, Brown J, Allan J, Ansell S . Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9(5):e327-e339. PMC: 10681157. DOI: 10.1016/S2352-3026(22)00072-2. View

18.

Rodgers T, Casulo C, Boissard F, Launonen A, Parreira J, Cartron G . Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies. Oncol Ther. 2021; 9(2):329-346. PMC: 8594248. DOI: 10.1007/s40487-021-00161-5. View

19.

Witzig T, Nowakowski G, Habermann T, Goy A, Hernandez-Ilizaliturri F, Chiappella A . A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015; 26(8):1667-77. DOI: 10.1093/annonc/mdv102. View

20.

Qualls D, Salles G . Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica. 2022; 107(1):19-34. PMC: 8719064. DOI: 10.3324/haematol.2021.278717. View